Biomolecular Concepts (May 2021)

Myosteatosis in NAFLD patients correlates with plasma Cathepsin D

  • Ding Lingling,
  • De Munck Toon. J. I.,
  • Oligschlaeger Yvonne,
  • dos Reis Inês Magro,
  • Verbeek Jef,
  • Koek Ger. H.,
  • Houben Tom,
  • Shiri-Sverdlov Ronit

DOI
https://doi.org/10.1515/bmc-2021-0004
Journal volume & issue
Vol. 12, no. 1
pp. 27 – 35

Abstract

Read online

Previously, we have shown that hepatic lipid accumulation induces the secretion of cathepsin D (CTSD), and that plasma CTSD levels are associated with increased inflammation and disease severity in nonalcoholic fatty liver disease (NAFLD). Although it is clear that the liver is a major source of plasma CTSD, it is unknown whether other metabolically active organs such as the muscle, also associate with plasma CTSD levels in NAFLD patients. Therefore, the aim of this study was to explore the relation between lipid accumulation in the muscle (myosteatosis) and plasma CTSD levels in forty-five NAFLD patients. We observed that hepatic steatosis positively associated with plasma CTSD levels, confirming the previously established link between plasma CTSD and the liver. Furthermore, a positive association between myosteatosis and plasma CTSD levels was observed, which was independent of sex, age, BMI, waist circumference and hepatic steatosis. By establishing a positive association between myosteatosis and plasma CTSD levels, our findings suggest that, in addition to the liver, the muscle is also linked to plasma CTSD levels in NAFLD patients. The observed link between myosteatosis and plasma CTSD levels supports the concept of a significant role of the skeletal muscle in metabolic disturbances in metabolic syndrome-related disorders.

Keywords